astellas
Leading Light for Life

5th July, 2013

Direct Healthcare Professional Communication

Diclofenac - new contraindications and warnings after a Europe-wide review of cardiovascular safety

Dear Healthcare professional,

This letter is sent in agreement with European Medicines Agency (EMA) and the Irish Medicines Board (IMB) to inform you of important restrictions to the use of diclofenac-containing medicines (systemic formulations), following completion of a Europe-wide review of its cardiovascular safety.

Summary

- **The benefits of diclofenac outweigh the risks, however, currently available data indicate an increase in arterial thrombotic risks associated with diclofenac, similar to that for selective COX-2 inhibitors.**
- **Diclofenac is now contraindicated in patients with established congestive heart failure (New York Heart Association, NYHA, classification II–IV), ischaemic heart disease, peripheral arterial disease or cerebrovascular disease. Patients with these conditions should have their treatment reviewed.**
- **Diclofenac treatment should only be initiated after careful consideration for patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, and smoking).**
- **The lowest effective dose of diclofenac should be used for the shortest duration necessary to control symptoms in all patients.**

Further information

Diclofenac is a widely used NSAID for relief of pain and inflammation. In 2012, the European Committee on Medicinal Products for Human Use (CHMP) considered the latest available data for the risk of cardiovascular side effects (such as heart attack or stroke) with non-selective NSAIDs. The Committee concluded that these data provided further evidence on the known risk with these medicines. Overall, the studies consistently indicated a small increased risk of cardiovascular side effects with diclofenac, similar to that seen with the COX-2 inhibitors.

As this conclusion raised safety concerns for diclofenac, the European Pharmacovigilance Risk Assessment Committee (PRAC) began an in-depth review on the cardiovascular safety of diclofenac in October 2012.

Academic research has been a central element of the reviews of NSAIDs and diclofenac. This includes an independent research project called 'safety of non-steroidal anti-inflammatory drugs' (SOS)[1], set up and funded by the European Commission's Seventh Framework Programme. Other groups have also been investigating the cardiovascular safety of NSAIDs, notably the Coxib and traditional NSAID Trialists' (CNT) collaborative group[2], who shared their results from a large meta-analysis of more than 600 randomised clinical trials with the Agency, and these were included in the PRAC's assessment of diclofenac. The group found that of 1000 patients allocated to diclofenac for a year, three more had major vascular events, compared to placebo.

Considering all evidence available, the PRAC supported the conclusions of the previous CHMP review and concluded that the benefits of diclofenac are considered to outweigh the risks. However, there is an increase in the risk of arterial thrombotic events associated with diclofenac, similar to that for selective COX-2 inhibitors. Therefore, new contraindications have been recommended in the product information for diclofenac, in line with measures in place for COX-2 inhibitors to help minimise cardiovascular risk.

The Summary of Product Characteristic (SmPC) and Package leaflet (PL) will be updated accordingly.

Call for reporting of adverse reactions

Healthcare professionals should report any suspected adverse reactions associated with the use of diclofenac in accordance with the national spontaneous reporting system. Suspected adverse reaction should be reported to the IMB using the online system (www.imb.ie) or via post:

Pharmacovigilance Section
Human Products Monitoring Department
Irish Medicines Board,
Kevin O'Malley House,
Earlsfort Centre,
Earlsfort Terrace,
Dublin 2,
Ireland.
Tel: 353-1-676 4971
Tel: 353-1-676 4976
Fax: 353-1-676 7836

Company contact point

For further inquiries concerning this information or if you would like to report a suspected adverse reaction to the company, please contact Astellas Pharma Co. Ltd. at the following phone number +353 1467 1555. Address:

Astellas Pharma Co. Ltd.
5 Waterside
Citywest Business Campus
Naas Road
Dublin 24
Co. Dublin
Tel: 0035314671555
Fax: 0035314671550
Email: Irishdrugsafety@astellas.com

[1] See www.sos-nsaids-project.org.
[2] See http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60900-9/abstract

astellas
Leading Light for Life

Yours sincerely,

Liz Bergin 022591

Dr. Liz Bergin MB., BAO, BCh., DME., DCH., DPM., MRCGP
Astellas Pharma Co. Ltd, Medical Director

Ralph Nies, MD
Astellas Pharma Europe B.V, European Qualified Person for Pharmacovigilance